Kesheng's Subsidiary Yikuang Announces Cumulative Acquisition of Bangte Biotech Shares Exceeding NT$300 Million Within One Year

1. Security Name: Bangte Biotechnology Co., Ltd.

2. Transaction Date: July 2, 2025 - July 1, 2026

3. Board Approval Date: Not applicable

4. Other Approval Date: Approval Level: Approved by Chairman July 1, 2026 (Minguo Year 115)

5. Transaction Quantity, Unit Price, and Total Amount: Transaction Quantity: 2,569,000 shares Unit Price: Average of NT$117.87 per share Total Transaction Amount: NT$302,811,565

6. Gain (or Loss) on Disposal (Not applicable for acquisition of securities): Not applicable

7. Relationship with the Target Company: Group company accounted for under the equity method

8. Cumulative Holdings of the Securities (including this transaction) to Date – Quantity, Amount, Ownership Percentage, and Restricted Rights (e.g., pledged): Bangte Biotechnology Co., Ltd.: Cumulative Holding Quantity: 2,606,000 shares Cumulative Holding Amount: NT$307,130,781 Ownership Percentage: 3.76% Restricted Rights Status: None

9. Proportion of cumulative securities investments (including this transaction) under Article 3 of the 'Asset Acquisition and Disposal Rules for Publicly Issued Companies' relative to the company’s total assets and equity attributable to owners of the parent in the latest financial statements, and the amount of working capital: Percentage of Total Assets: 0.77% Percentage of Equity Attributable to Owners of the Parent: 1.18% Working Capital Amount: -NT$36,036,990 thousand

10. Specific Purpose of Acquisition or Disposal: In alignment with the group's strategic transformation

11. Dissenting Director's Opinion on this Transaction: None

12. Whether this Transaction is a Related-Party Transaction: No

13. Counterparty and its Relationship with the Company: None

14. Date of Supervisor's Approval or Audit Committee's Consent: Not applicable

15. Previous Date of Material Information Disclosure on the Same Event: Not applicable

16. Other Explanatory Matters: None